Moderna and Merck say mRNA cancer vaccine succeeded in late-stage melanoma trial
The personalized mRNA cancer vaccine, added to Merck's Keytruda, slowed the return of melanoma and its spread to other parts of the body in the study.
Comments (0)
No comments yet